Unmet Needs and Therapy Modifications Relevant in the CRC Landscape
John L. Marshall, MD, discusses unmet needs in the targeted therapy space and the importance of optimizing dosing in colorectal cancer.
Related Articles
Mature Data Confirm Benefit of Early Rituximab vs Watchful Waiting in Asymptomatic Follicular Lymphoma
Long-term data confirms early rituximab significantly delays new treatment for advanced, asymptomatic, low-burden follicular lymphoma compared to watchful waiting. Maintenance rituximab showed no added benefit…
Phase 1 GTB-3650 Trial Advances for CD33+ Malignancies
Cohort 1 of the GTB-3650 phase 1 trial completed with no safety issues observed in patients with CD33-expressing hematologic malignancies.
TIL Therapy: A New Era for Advanced Melanoma Treatment
Anuradha Krishnamurthy, MBBS, provides backgrounds on TILs and discusses their critical role in the advanced melanoma treatment landscape.
Hope on the Horizon: Brain Cancer Advances in Awareness Month
Manmeet Ahluwalia, MD, MBA, FASCO, discussed the importance of Brain Cancer Awareness Month for a community oncologist audience.
ASCO 2025 Preview: Practice-Changing Trials to Watch
As the oncology community prepares for the 2025 American Society of Clinical Oncology Annual Meeting, anticipation is running high over a wave of potential practice-changing…
Roundtable Roundup: Early CAR T-cell Therapy in Multiple Myeloma
In separate live virtual events, Sarah A. Holstein, MD, PhD, and Shashank Cingam, MD, discuss options for a patient with relapsed/refractory multiple myeloma and the…
FDA’s Project Optimus Drives Increased Dose Optimization in Early Trials
Deepak Bhamidipati, MD, discusses the impact of the FDA’s Project Optimus on early-phase drug development protocols.
Dermatological Complications of JAK Inhibitors: Monitoring and Management
Panelists discuss how JAK inhibitor therapy, while effective in treating myelofibrosis and other hematologic disorders, increases the risk of skin cancers, particularly non-melanoma skin cancers,…
Myeloma Research Sees Transformation Following ODAC Support For MRD End Point
In an interview with Targeted Oncology, C. Ola Langren, MD, PhD, discussed the continuing impact of the groundbreaking FDA ODAC vote, the future of the…
Lurbinectedin Combo Boosts Survival in ES-SCLC Maintenance
Lurbinectedin plus atezolizumab maintenance significantly improved PFS & OS in extensive-stage SCLC, offering a potential new standard of care.